S. 705 · 119th Congress · Health

Innovation in Pediatric Drugs Act of 2025

In committee1.8k words Introduced Feb 25, 2025 · Latest action Feb 25, 2025

How far it has goneStage 2 of 6
  1. IntroducedFeb 25, 2025 Done
  2. CommitteeReferred to Health, Education, Labor, and Pensions Current stage
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to require pediatric studies on certain orphan drugs and to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements.

Specifically, the bill would impose pediatric study requirements on drugs for rare diseases or conditions (i.e., orphan drugs) if the FDA determines that (1) the drug could improve the treatment, diagnosis, or prevention of a disease compared with currently available products for the relevant pediatric population; or (2) there is a need for additional options within the drug’s class or indication. (Under current law, pediatric study requirements generally do not apply to orphan drugs.) The FDA must issue guidance describing how these changes will be implemented, including information on how waivers will be granted.

The bill also permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirements.

Additionally, the bill authorizes the National Institutes of Health to allot a certain amount of funds for priority pediatric research, including research on drugs with no remaining patents on which pediatric studies are needed.

Finally, the Government Accountability Office must report on the bill’s impact on rare disease drug development and on the availability of pediatric information on orphan drugs.

Congressional Research Service · summary of “Introduced in Senate” version · Feb 25, 2025

Who lobbies on it

4 organizations, more than 88% of Senate bills · 11 filings · Q1 2025–Q3 2026

See which of this bill’s sponsors and cosponsors got money from the lobbying organizations’ PACs → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Biotechnology Innovation Organization 4 of 7 quarters
    “…S.705: Innovation in Pediatric Drugs Act of 2025 ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit ---Retaining Access and Restoring Exclusivity (RARE) Act Pandemic Preparedness ---Drug Supply Chain Management ---R&D Funding for Medical…”

    $6.5M lobbying spend in 2026 to date, all issuesQ2 2026 filing

  2. Glaxosmithkline Llc 3 of 7 quarters
    “Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b) program.”

    $1.6M lobbying spend in 2025, all issuesQ4 2025 filing

  3. American Society of Anesthesiologists 2 of 7 quarters
    “…S. 705, Specialty Physicians Advancing Rural Care (SPARC) Act: physician shortages in rural areas Public Law No. 113-5, Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA): preparedness for public health Lorna Breen Reauthorization H.R.27, HALT Fentanyl Act: fentanyl scheduling and registration…”

    $1.0M lobbying spend in 2025, all issuesQ2 2025 filing

1 more organization, every filingPROUpgrade

Organizations that named S. 705 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Feb 25, 2025Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1347)
  2. Feb 25, 2025Introduced in Senate